Moleculin Biotech’s (NASDAQ:MBRX) WP1066 received FDA rare pediatric disease indication for the treatment of diffuse intrinsic pontine glioma (DIPG), medulloblastoma and atypical teratoid rhabdoid tumor. WP1066 is an...
Ovid Therapeutics (NASDAQ: OVID) reported that its Phase 3 NEPTUNE trial evaluating OV101 for the treatment of Angelman syndrome failed to meet its primary endpoint. Angelman syndrome is a rare genetic disorder that...
Profound Medical’s (NASDAQ:PROF; TSX:PRN) Sonalleve received FDA humanitarian device exemption (HDE) approval for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that occurs most often in...
Urovant Sciences (NASDAQ:UROV) reported disappointing topline results from its Phase 2b trial of vibegron for the treatment of abdominal pain due to irritable bowel syndrome (IBS) in women. The study failed to meet its...
Closely-held KA Imaging introduced a new hardware subscription model to help U.S. and Canadian hospitals acquire Reveal 35C, the company’s portable X-ray device, during the pandemic. Reveal 35C is a portable, single...
The FDA cleared Neuronetics’ (NASDQ:STIM) TouchStar protocol for the treatment of major depressive disorder. TouchStar is a three-minute intermittent theta burst protocol administered using the company’s NeuroStar...
Capricor Therapeutics (NASDAQ:CAPR) dosed the first two patients in its Phase 2 trial evaluating CAP-1002 for the treatment of severe COVID-19. CAP-1002 is an intravenously delivered allogeneic cardiac cell therapy...
Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) began screening patients for its two Phase 3 trials evaluating ORMD-0801 for the treatment of Type 2 diabetes. The trials will enroll a total of 1,125 Type 2 diabetes patients...
The FDA granted PolyPid’s (NASDAQ:PYPD) D-PLEX100 breakthrough therapy designation for the prevention of surgical site infections in patients undergoing colorectal surgery. D-PLEX100 is designed to provide prolonged...
The FDA cleared Orchard Therapeutics’ (NASDAQ:ORTX) IND for OTL-200, a stem cell-based gene therapy for the treatment of metachromatic leukodystrophy (MLD). MLD is caused by a mutation in the arylsulfatase-A gene, which...
The FDA approved Eiger BioPharmaceuticals’ (NASDAQ:EIGR) Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. Progeria is an extremely rare and fatal disease caused by a...
Seelos Therapeutics’ (NASDAQ:SEEL) SLS-005 (trehalose) received FDA orphan drug designation for the treatment of amyotrophic lateral sclerosis (ALS). Trehalose is a low molecular weight disaccharide that crosses the...
Kintara Therapeutics (NASDAQ:KTRA) reported interim data from two Phase 2 trials evaluating VAL-083 for the treatment of glioblastoma multiforme (GBM). In the first Phase 2 study, newly diagnosed patients receiving VAL...
Selecta Biosciences’ (NASDAQ:SELB) MMA-101 received FDA orphan drug designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in the methylmalonyl-CoA mutase gene, which results in the...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that an independent data safety monitoring board (DSMB) approved the continuation of the company’s Phase 2a ‘AMBITION’ clinical trial to the next dose level cohort. After...
At the Society for Neuro-Oncology annual meeting, Kazia Therapeutics (NASDAQ:KZIA) presented positive interim data from its Phase 2 trial evaluating paxalisib for the treatment of diffuse intrinsic pontine glioma...
Milestone Pharmaceuticals (NASDAQ:MIST) enrolled the first patient in its Phase 3 RAPID trial evaluating etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). PSVT is characterized by...
Chiasma (NASDAQ:CHMA) reported positive topline results from its Phase 3 trial evaluating MYCAPSSA for the treatment of acromegaly. Designed to support a planned marketing authorization application in the EU, the non...
Synthetic Biologics (NYSE American:SYN) engaged Alliance Global Partners as an advisor to help the company evaluate strategic alternatives. The company is considering a variety of options, including an acquisition...
BrainStorm Cell Therapeutics’ (NASDAQ:BCLI) NurOwn failed to meet its primary and secondary endpoints in a Phase 3 amyotrophic lateral sclerosis (ALS) trial. NurOwn consists of mesenchymal stromal cells (MSCs) that have...
Closely-held PharmaJet’s needle-free injection system will be used to deliver Diomics’ Diocheck SARS-CoV-2 visual immune response indicator. Diomics’ immune response indicator will be injected under the skin using...
Adamis Pharmaceuticals (NASDAQ:ADMP) received a second complete response letter (CRL) from the FDA regarding its ZIMHI high dose naloxone injection product for the treatment of opioid overdose. The FDA issued its first...